These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 30853334)

  • 1. Targeting DNA Methylation and EZH2 Activity to Overcome Melanoma Resistance to Immunotherapy.
    Emran AA; Chatterjee A; Rodger EJ; Tiffen JC; Gallagher SJ; Eccles MR; Hersey P
    Trends Immunol; 2019 Apr; 40(4):328-344. PubMed ID: 30853334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive analysis of tumor necrosis factor receptor TNFRSF9 (4-1BB) DNA methylation with regard to molecular and clinicopathological features, immune infiltrates, and response prediction to immunotherapy in melanoma.
    Fröhlich A; Loick S; Bawden EG; Fietz S; Dietrich J; Diekmann E; Saavedra G; Fröhlich H; Niebel D; Sirokay J; Zarbl R; Gielen GH; Kristiansen G; Bootz F; Landsberg J; Dietrich D
    EBioMedicine; 2020 Feb; 52():102647. PubMed ID: 32028068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment.
    Tsukamoto H; Fujieda K; Miyashita A; Fukushima S; Ikeda T; Kubo Y; Senju S; Ihn H; Nishimura Y; Oshiumi H
    Cancer Res; 2018 Sep; 78(17):5011-5022. PubMed ID: 29967259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EZH2 Cooperates with DNA Methylation to Downregulate Key Tumor Suppressors and IFN Gene Signatures in Melanoma.
    Tiffen J; Gallagher SJ; Filipp F; Gunatilake D; Emran AA; Cullinane C; Dutton-Register K; Aoude L; Hayward N; Chatterjee A; Rodger EJ; Eccles MR; Hersey P
    J Invest Dermatol; 2020 Dec; 140(12):2442-2454.e5. PubMed ID: 32360600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma.
    Vilain RE; Menzies AM; Wilmott JS; Kakavand H; Madore J; Guminski A; Liniker E; Kong BY; Cooper AJ; Howle JR; Saw RPM; Jakrot V; Lo S; Thompson JF; Carlino MS; Kefford RF; Long GV; Scolyer RA
    Clin Cancer Res; 2017 Sep; 23(17):5024-5033. PubMed ID: 28512174
    [No Abstract]   [Full Text] [Related]  

  • 6. PD-L1 methylation regulates PD-L1 expression and is associated with melanoma survival.
    Micevic G; Thakral D; McGeary M; Bosenberg MW
    Pigment Cell Melanoma Res; 2019 May; 32(3):435-440. PubMed ID: 30343532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bispecific Antibody Approach for Improved Melanoma-Selective PD-L1 Immune Checkpoint Blockade.
    Koopmans I; Hendriks MAJM; van Ginkel RJ; Samplonius DF; Bremer E; Helfrich W
    J Invest Dermatol; 2019 Nov; 139(11):2343-2351.e3. PubMed ID: 31128201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Somatic Copy Number Amplification and Hyperactivating Somatic Mutations of EZH2 Correlate With DNA Methylation and Drive Epigenetic Silencing of Genes Involved in Tumor Suppression and Immune Responses in Melanoma.
    Tiffen J; Wilson S; Gallagher SJ; Hersey P; Filipp FV
    Neoplasia; 2016 Feb; 18(2):121-32. PubMed ID: 26936398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Histone Methyltransferase Ezh2 Controls Mechanisms of Adaptive Resistance to Tumor Immunotherapy.
    Zingg D; Arenas-Ramirez N; Sahin D; Rosalia RA; Antunes AT; Haeusel J; Sommer L; Boyman O
    Cell Rep; 2017 Jul; 20(4):854-867. PubMed ID: 28746871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy.
    Peng D; Kryczek I; Nagarsheth N; Zhao L; Wei S; Wang W; Sun Y; Zhao E; Vatan L; Szeliga W; Kotarski J; Tarkowski R; Dou Y; Cho K; Hensley-Alford S; Munkarah A; Liu R; Zou W
    Nature; 2015 Nov; 527(7577):249-53. PubMed ID: 26503055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EZH2 negatively regulates PD-L1 expression in hepatocellular carcinoma.
    Xiao G; Jin LL; Liu CQ; Wang YC; Meng YM; Zhou ZG; Chen J; Yu XJ; Zhang YJ; Xu J; Zheng L
    J Immunother Cancer; 2019 Nov; 7(1):300. PubMed ID: 31727135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolution of delayed resistance to immunotherapy in a melanoma responder.
    Liu D; Lin JR; Robitschek EJ; Kasumova GG; Heyde A; Shi A; Kraya A; Zhang G; Moll T; Frederick DT; Chen YA; Wang S; Schapiro D; Ho LL; Bi K; Sahu A; Mei S; Miao B; Sharova T; Alvarez-Breckenridge C; Stocking JH; Kim T; Fadden R; Lawrence D; Hoang MP; Cahill DP; Malehmir M; Nowak MA; Brastianos PK; Lian CG; Ruppin E; Izar B; Herlyn M; Van Allen EM; Nathanson K; Flaherty KT; Sullivan RJ; Kellis M; Sorger PK; Boland GM
    Nat Med; 2021 Jun; 27(6):985-992. PubMed ID: 33941922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Translational control of tumor immune escape via the eIF4F-STAT1-PD-L1 axis in melanoma.
    Cerezo M; Guemiri R; Druillennec S; Girault I; Malka-Mahieu H; Shen S; Allard D; Martineau S; Welsch C; Agoussi S; Estrada C; Adam J; Libenciuc C; Routier E; Roy S; Désaubry L; Eggermont AM; Sonenberg N; Scoazec JY; Eychène A; Vagner S; Robert C
    Nat Med; 2018 Dec; 24(12):1877-1886. PubMed ID: 30374200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy.
    Hailemichael Y; Woods A; Fu T; He Q; Nielsen MC; Hasan F; Roszik J; Xiao Z; Vianden C; Khong H; Singh M; Sharma M; Faak F; Moore D; Dai Z; Anthony SM; Schluns KS; Sharma P; Engelhard VH; Overwijk WW
    J Clin Invest; 2018 Apr; 128(4):1338-1354. PubMed ID: 29480817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alternative macrophage polarisation associated with resistance to anti-PD1 blockade is possibly supported by the splicing of FKBP51 immunophilin in melanoma patients.
    Troiani T; Giunta EF; Tufano M; Vigorito V; Arrigo P; Argenziano G; Ciardiello F; Romano MF; Romano S
    Br J Cancer; 2020 Jun; 122(12):1782-1790. PubMed ID: 32317723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade.
    Shergold AL; Millar R; Nibbs RJB
    Pharmacol Res; 2019 Jul; 145():104258. PubMed ID: 31063806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overcoming Immune Checkpoint Blockade Resistance via EZH2 Inhibition.
    Kim HJ; Cantor H; Cosmopoulos K
    Trends Immunol; 2020 Oct; 41(10):948-963. PubMed ID: 32976740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Era of Checkpoint Inhibition: Lessons Learned from Melanoma.
    Paschen A; Schadendorf D
    Recent Results Cancer Res; 2020; 214():169-187. PubMed ID: 31473853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Positive Correlation Between the EZH2 and PD-L1 Expression in Resected Lung Adenocarcinomas.
    Toyokawa G; Takada K; Tagawa T; Hamamoto R; Yamada Y; Shimokawa M; Oda Y; Maehara Y
    Ann Thorac Surg; 2019 Feb; 107(2):393-400. PubMed ID: 30343006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.